Literature DB >> 34780600

Robust thrombolytic and anti-inflammatory action of a constitutively active ADAMTS13 variant in murine stroke models.

Kieron South1,2, Ohud Saleh1,2,3, Eloise Lemarchand1,2, Graham Coutts1,2, Craig J Smith2,4,5, Ingo Schiessl1,2, Stuart M Allan1,2.   

Abstract

Advances in our understanding of ADAMTS13 structure, and the conformation changes required for full activity, have rejuvenated the possibility of its use as a thrombolytic therapy. We have tested a novel Ala1144Val ADAMTS13 variant (constitutively active [ca] ADAMTS13) that exhibits constitutive activity, characterized using in vitro assays of ADAMTS13 activity, and greatly enhanced thrombolytic activity in 2 murine models of ischemic stroke, the distal FeCl3 middle cerebral artery occlusion (MCAo) model and transient middle cerebral artery occlusion (tMCAO) with systemic inflammation and ischemia/reperfusion injury. The primary measure of efficacy in both models was restoration of regional cerebral blood flow (rCBF) to the MCA territory, which was determined using laser speckle contrast imaging. The caADAMTS13 variant exhibited a constitutively active conformation and a fivefold enhanced activity against fluorescence resonance energy transfer substrate von Willebrand factor 73 (FRETS-VWF73) compared with wild-type (wt) ADAMTS13. Moreover, caADAMTS13 inhibited VWF-mediated platelet capture at subphysiological concentrations and enhanced t-PA/plasmin lysis of fibrin(ogen), neither of which were observed with wtADAMTS13. Significant restoration of rCBF and reduced lesion volume was observed in animals treated with caADAMTS13. When administered 1 hour after FeCl3 MCAo, the caADAMTS13 variant significantly reduced residual VWF and fibrin deposits in the MCA, platelet aggregate formation, and neutrophil recruitment. When administered 4 hours after reperfusion in the tMCAo model, the caADAMTS13 variant induced a significant dissolution of platelet aggregates and a reduction in the resulting tissue hypoperfusion. The caADAMTS13 variant represents a potentially viable therapeutic option for the treatment of acute ischemic stroke, among other thrombotic indications, due to its enhanced in vitro and in vivo activities that result from its constitutively active conformation.
© 2022 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 34780600     DOI: 10.1182/blood.2021012787

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   25.476


  4 in total

Review 1.  Central Nervous System Pericytes Contribute to Health and Disease.

Authors:  Francesco Girolamo; Mariella Errede; Antonella Bizzoca; Daniela Virgintino; Domenico Ribatti
Journal:  Cells       Date:  2022-05-20       Impact factor: 7.666

Review 2.  Neuroprotective Effects of Quercetin on Ischemic Stroke: A Literature Review.

Authors:  Leilei Zhang; Jingying Ma; Fan Yang; Sishi Li; Wangran Ma; Xiang Chang; Lin Yang
Journal:  Front Pharmacol       Date:  2022-05-18       Impact factor: 5.988

3.  Constitutively active ADAMTS13: An emerging thrombolytic agent for acute ischemic stroke.

Authors:  Manasa K Nayak; Gagan D Flora; Anil K Chauhan
Journal:  J Thromb Haemost       Date:  2022-02-02       Impact factor: 16.036

4.  Residues R1075, D1090, R1095, and C1130 Are Critical in ADAMTS13 TSP8-Spacer Interaction Predicted by Molecular Dynamics Simulation.

Authors:  Zhiwei Wu; Junxian Yang; Xubin Xie; Guangjian Liu; Ying Fang; Jianhua Wu; Jiangguo Lin
Journal:  Molecules       Date:  2021-12-12       Impact factor: 4.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.